oremepermin alfa (KP-100) / Kringle - LARVOL DELTA

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar (clinicaltrials.gov) - P3 | N=62 | Recruiting | Sponsor: Kringle Pharma, Inc. | Trial completion date: Aug 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar (clinicaltrials.gov) - P3 | N=62 | Recruiting | Sponsor: Kringle Pharma, Inc. | Trial completion date: Nov 2025 ➔ Aug 2026 | Trial primary completion date: Sep 2024 ➔ Jan 2026

Trial completion date • Trial primary completion date

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar (clinicaltrials.gov) - P3 | N=62 | Recruiting | Sponsor: Kringle Pharma, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury (clinicaltrials.gov) - P3 | N=25 | Recruiting | Sponsor: Kringle Pharma, Inc. | Trial primary completion date: Mar 2023 ➔ Dec 2022

Trial primary completion date • CNS Disorders • Orthopedics

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury (clinicaltrials.gov) - P3 | N=25 | Recruiting | Sponsor: Kringle Pharma, Inc. | Trial completion date: Sep 2022 ➔ Jun 2023 | Trial primary completion date: Sep 2020 ➔ Mar 2023

Trial completion date • Trial primary completion date • CNS Disorders • Orthopedics

Kringle Pharma-Continued extension End of final observation date for Phase 2 study in ALS [Google translation] (Yahoo Finance) - "The company is conducting a phase 2 clinical trial of the recombinant human HGF protein (development code: KP-100IT) being developed at 12:00 on the 9th at Tohoku University Hospital and Osaka University Hospital for ALS patients. Announced that the final observation date for the final case of (doctor-led clinical trial) has ended."

New P2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury (clinicaltrials.gov) - P3; N=25; Recruiting; Sponsor: Kringle Pharma, Inc.

Clinical • New P3 trial • Complement-mediated Rare Disorders • Orthopedics

Hepatoprotective Activity of InlB321/15, the HGFR Ligand of Bacterial Origin, in CCI4-Induced Acute Liver Injury Mice. (PubMed, Biomedicines) - "Both InlB321/15 and rhHGF improved macroscopic liver parameters (liver mass was 1.51, 1.27 and 1.15 g for the vehicle, InlB321/15 and rhHGF, respectively, p < 0.05), reduced necrosis (24.0%, 16.18% and 21.66% of the total area for the vehicle, InlB321/15 and rhHGF, respectively, p < 0.05). Obtained data suggest that InlB321/15 is a promising candidate for a tissue repair agent."

Journal • Preclinical

Impaired Wound Healing of Alveolar Lung Epithelial Cells in a Breathing Lung-On-A-Chip. (PubMed, Front Bioeng Biotechnol) - "This impairment could be partially ameliorated by administration of rhHGF. This proof-of-concept study provides a way to study of more complex interactions, such as a co-culture with fibroblasts, endothelial cells, or immune cells, as well as the study of wound healing at an air-liquid interface."

Journal